Book a Demo
Yan Wang
Gray shield icon
Is this you?
Claim your profile.

Yan Wang

AS SEEN ON
Respiratory Medical, Asia-Pacific Journal of Oncology Nursing (APJON), ijidonline.com, MDPI, Nature Portfolio

Geo Focus

Coverage Attributes:

Beta
Informative: 51 %
Data Driven: 46 %

Themes Covered:

Not enough data icon

Not enough data

Most Recent Topics:

  • Biology & Life Sciences
  • Chemistry
  • Materials Science
  • Biotechnology
  • Environmental Engineering
  • Physics
  • Neuroscience
  • Zoology

Pitching Insights

Yan Wang’s coverage primarily focuses on scientific and healthcare topics, particularly medical research, biology, genetics, diseases, and treatments. The majority of the articles cite data extensively.

Given her focus on citing data and the highly technical nature of the topics covered, Yan is likely to be interested in pitches from experts with a strong background in medical research or specific scientific fields related to the topics she covers. Pitches offering access to new data or insights derived from rigorous scientific studies may resonate well with her.

While there's no specified geographic focus for Yan's articles, it's important that any pitches align closely with her area of expertise which revolves around science and healthcare-related subjects.

This information evolves through artificial intelligence and human feedback. Improve this profile .

Journalists With Similar Coverage:

Based on similarity of content.
Wei Wang

Wei Wang

******ng@********au
Publications
Nature Portfolio, Cell Press, annalsofvascularsurgery.com, Extrica, Cureus Journal of Medical Science
Most recent topics
Not enough data

Articles

BMJ

Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial

Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial

By: Lingfang Xia, Yu Xu, Ruiyan Wu, Juefeng Wan, Shujuan Zhou, Jiaojie Lv, Zhen Zhang, Liu, Yong Chen, Fangqi Liu, Xuebing Jiang, Lijun Shen, Zhiyuan Zhang, Yan Wang

Introduction Mucosal melanoma (MM) carries a high risk of postoperative relapse and poorer survival than cutaneous disease. Prospective data from China support adjuvant temozolomide–cisplatin (TMZ/DDP) in resected MM, while radiotherapy (RT) may augment antitumour immunity and synergise with programmed death 1 (PD-1) inhibitor. We therefore designed an adjuvant regimen combining short-course RT (SCRT) with chemotherapy and PD-1 inhibitor after curative-intent resection.Methods and analysis This investigator-initiated, single-arm, prospective, phase II study at Fudan University Shanghai Cancer Centre enrols adults (≥18 years) with histologically confirmed MM after R0/R1 resection, Eastern Cooperative Oncology Group (ECOG) performance status 0–1 and M0 disease. Patients receive six 3-week cycles of systemic therapy: pucotenlimab 200 mg IV on day 1; TMZ 200 mg/m² orally on days 1–5 and DDP 25 mg/m² IV on days 1–3. (SCRT; 25 Gy in five fractions) is delivered after the first two cycles of systemic therapy, followed by four additional cycles of systemic therapy without RT. The primary endpoint is 1-year recurrence-free survival (RFS). Secondary endpoints include locoregional RFS, distant metastasis-free survival, overall survival and safety (CTCAE V.5.0). The planned sample size is 47 (44 evaluable), providing 80% power (one-sided α of 0.10) to detect an improvement in 1-year RFS from 55% to 70%. Time-to-event endpoints will be estimated using Kaplan–Meier methods with 95% CIs.Ethics and dissemination The protocol was approved by the Ethics Committee of Fudan University Shanghai Cancer Centre (approval number: 2407300-5), and all participants will provide written informed consent. Findings will be disseminated in peer-reviewed journals and at scientific conferences.Trial registration number ChiCTR2400093001.

© 2026 Intelligent Relations